ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.

The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.

ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.

ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.

ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.

ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.

Analysts currently set an average price target of 150.64 USD for the ICON stock (median: 132.60 USD), implying -7.9 % versus the latest price. The consensus is based on 24 analyst ratings.

ICON Analyst Price Targets 2026

24 analysts currently rate the ICON stock: 14 recommend buying, 9 holding and 1 selling. For 2026, analysts expect ICON to generate revenue of 8.06 B USD and earnings per share of 11.54 USD.

ICON Analyst Price Targets 2026

Converted at the current exchange rate, the ICON share trades at 141.76 EUR (163.57 USD).

The ICON share (ICLR) is listed on 4 stock exchanges, including: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).

ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.

The expected revenue of ICON is 8.06 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ICON is 883.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ICON is currently 14.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ICON stock.

The price-to-sales ratio (P/S) of ICON is currently 1.55. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ICON stock.

The Eulerpool Quality Score for ICON is 3/10.

The ISIN of ICON is IE0005711209. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ICON is 932242. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ICON is ICLR. The ticker symbol is used to trade ICON shares on the stock exchange.

ICON paid dividends every year for the past 0 years.

ICON is assigned to the 'Health' sector.

The dividends of ICON are distributed in USD.